In an independent study recently published by Pfizer, [1] natural killer (NK) immune cells sourced from HemaCare were evaluated to test how well suited they are for use in cytotoxic activity assays.
These last few years have seen the successful clinical development of several monoclonal antibody-based treatments for cancer and inflammatory disease. These antibodies are designed to act in a number of different ways, from tagging target cells so they can be recognized by the immune system, to blocking growth or metastasis, to attacking problematic cells themselves. Monoclonal antibodies (m’Abs) are seen as particularly beneficial because they can be used to complement more traditional therapies and because their use generally results in fewer side effects.